19
Jun
2024

Hubei Biocause Heilen Pharmaceutical Co., Ltd

Exhibitor at CPHI & PMEC China 2024 stand E2A38, Contract Services
About Us

Hubei Biocause Pharma is one leading API producer in China with  two API sites &one R&D center, inspected and approved 7 times by US FDA and 4 times by EU GMP.We produce Abiraterone Acetate,   Ibuprofen, Milrinone, Fludarabine, Granisetron, Flumazenil and etc. The product has been exported to over 85 countries globally and half of them sold into regulatory market as USA and EU.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI & PMEC China 2024
  • 19 June 2024 - 21 June 2024
  • Shanghai New International Expo Center
  • Visit us at stand E2A38, Contract Services

Products Featured at CPHI & PMEC China 2024

  • Abiraterone Acetate

    Product Abiraterone Acetate

    oncology 
  • Azacytidine

    Product Azacytidine

    Oncology
  • Cladribine

    Product Cladribine

    Hubei granules- biocause pharmaceutical co. Ltd offers a wide range of products which includes cladribine. Contact us for more information.
  • Decitabine

    Product Decitabine

    Oncology
  • Fludarabine phosphate

    Product Fludarabine phosphate

    Hubei granules- biocause pharmaceutical co. Ltd offers a wide range of products which includes fludarabine phosphate. Contact us for more information.